Get Permission Rudhan and Biswal: Do Lung surfactant proteins play a role in severity of bronchiolitis


Introduction

Bronchiolitis is the most frequent cause of lower respiratory tract illness and hospitalization in young infants.1 It is a viral inflammatory condition of bronchioles mostly in children below two years of age and is characterized by progressive tachypnea, nasal flaring, intercostal, subcostal, & sub sternal retractions leading to severe breathing difficulty.2, 3 RSV accounts for 63% of illness; whereas other viruses i.e. human metapneumovirus, influenza virus, Para influenza virus, adenovirus, rhinovirus coronavirus, and bocavirus are responsible in many a cases.4

Pulmonary surfactant is a multimolecular complex consisting of phospholipids and cholesterol (total 90%) and surfactant proteins (SP-A, SP-B, SP-C and SP-D) (10%) which forms a lattice called tubular myelin that covers the alveolar surface.5 Initially, these proteins were known for their traditional role in reducing surface tension at the air-liquid interface, preventing alveolar collapse during expiration of the lung. The hydrophilic protein SP-A and SP-D belong to collagenous and superfamily of C-type lectin binding domains associated with pulmonary homeostasis and innate immunity.6, 7, 8 The SP-A and SP-D function as pattern recognition molecules; often bind using their carbohydrate recognition domain (CRD) to oligosaccharides on the surface of microorganisms to promote phagocytosis. The immune action of SP-A and SP-D includes induction of pathogens agglutination, preventing pathogens adherence to the cell surface, balancing the activation and inhibition of infectious colonization and invasion. It also activates the lung inflammatory process, regulates the release of oxygen radicals, pro and anti-inflammatory cytokines.7 They have been postulated to play a role in bronchiolitis.8, 9, 10, 11, 12, 13 The aim of this study was to evaluate the significance of the levels of SP-A and SP-D in cases of bronchiolitis.

Table 1

Bronchiolitis Severity Score

Jlh0

Items

Score 1

Score 2

Score 3

1

Respiratory Rate

1 – 2 month

2month – 1Year

> 1Year

<60

<50

<40

61-69

51-59

41-44

>70

>60

>45

2

Cyanosis

Normal

Peripheral

central

3

SPO2

>93-96%

90-93%

<90%

4

Sensorium

Mild irritable but Easy to console

Difficulty to console

Lethargy/Drowsy

5

Nasal flare/ Retraction (SC, IC, SCS)

1 of 4

2 of 4

3 or more

6

Feeding

Normal

>50%

<50%

7

Air entry /Wheeze

Normal, Scattered Rhonchi, crepitation end expiratory

Fair, Rhonchi, Rales in both inspiration and expiration

Poor, Grunt, Rhonchi and Crepitation

Table 2

Serumlevels of Surfactant Protein A & D.

Case

(Mean ±SD)

Control

(Mean ±SD)

P value*

SP - A

0.16 ± 0.0028

0.17 ± 0.0009

< 0.0001

SP - D

0.12 ± 0.001

0.10± 0.043

0.046

Materials and Methods

Infants under 2years of age with bronchiolitis were recruited in pediatrics casualty and outpatient department of JIPMER, Puducherry. Consecutive Infants diagnosed as bronchiolitis were categorized into non-severe (n=30) and severe (n=30) bronchiolitis using Bronchiolitis Severity score14, 15 (Supplementary Table 1) as controls and cases respectively after obtaining informed consent with age and gender matched. All the samples were collected on the 2nd or 3rd day of illness.

Quantifying Serum SP-A and SP-D levels

One milliliter (1ml) blood was collected, centrifuged at 3000rpm for 10mins and separated serum was stored at -40oC. The sandwich ELISA kit (SP-A – E3802Hu and SP-D – E3597Hu) from Bioassay Technology Laboratory was used for accurate quantification of serum levels of SP-A and SP-D as per the manual instruction.

Ethics

This study was approved by Institute Ethics Committee (Human studies) Ref No: JIP/IEC/2015/13/544. Written informed consent was obtained from all the parents before participation.

Statistical analysis

Analyses were performed using Graphpad prism version 6. Variables like age and weight were expressed in mean and other variables were described in frequency and percentage. Un-paired t-test was used to compare the levels of SP-A and SP D in case and control. The P value <0.05 was consider as significant.

Results

The mean age in both groups was 5months (1month – 10 months) and each group has 20 male and 10 female infants with the mean weight of 5.6±1.3 and 5.75±1.9Kg in control and case groups respectively. In Case group 70% belong to joint family, 50% lies in upper lower class status, 84% live in rural areas whereas 57% belong to joint family, 50% lies in lower middle class status, 74% live in rural areas in control group.

The SP A levels were significantly reduced in severe cases (0.16ng/L ± 0.0028) compared to non-severe cases (0.17ng/L ± 0.0009) (p <0.0001) and SP D levels were significantly higher in severe cases (0.12ng/ml ± 0.001) compared to non-severe cases (0.10ng/ml ± 0.043) (p <0.05) (Table 2). The levels of SP-A and SP-D in different viruses.

Discussion

In this study the mean serum SP-A level was significantly reduced whereas the mean serum SP-D level was significantly higher in severe cases compared to the controls irrespective of the infecting virus. Synthesis of surfactant protein by type II pneumocytes is reduced due to the viral invasion. At the same time the SP- A binds to viruses and opsonin by alveolar macrophages for phagocytosis and viral clearance.16 It is also associated with reduced immunity and increased severity.17 This is similar to the conclusion drawn from other studies across the world.8, 10, 18

The elevated levels of SP-D in severe cases in our study have also been observed in studies conducted in Japan and Korea. 13, 19 However the result also disagrees with some Scottish and Brazilian studies.8, 10 Pulmonary SP-D concentrations may vary during the progress of viral infection. It may rise in the early viral infection to enhance phagocytosis.12 It has been found that alveolar macrophages and viruses have an identical binding site. Therefore, SP-D binding via its CRDs to virus may inhibit the link of SP-D to alveolar macrophages.16 Though SP- D has similar role of SP-A in host immune mechanism, SP-A contribute pulmonary defense via the alveolar macrophages, whereas SP-D preform via the neutrophils. After viral invasion, onset of inflammation causes hyperplasia of type II pneumocytes and damage the alveolar epithelium which secrets excess SP-D. At the same time inflammation produce immense amount of neutrophils and SP-D encourage these cells and thereby contribute to the viral clearance.13, 16

Conclusion

Reduced level of SP-A and the elevated level of SP-D was associated with severe pulmonary inflammation and infection in bronchiolitis. Thus variation in levels of SP-A and SP-D might play a major role in the pathogenesis of severe bronchiolitis.

Conflicts of Interest

All contributing authors declare no conflicts of interest.

Source of Funding

None.

References

1 

M T Caballero F P Polack R T Stein Viral bronchiolitis in young infants: new perspectives for management and treatmentJ Pediatr (Rio J)2017937583

2 

I Chkhaidze D Zirakishvili Acute Viral Bronchiolitis in Infants (Review)Georgian Med News20172644350

3 

JT Verger EE Verger Respiratory Syncytial Virus Bronchiolitis in ChildrenCrit Care Nurs Clin North Am 20122445557210.1016/j.ccell.2012.07.008

4 

G Piedimonte MK Perez Respiratory Syncytial Virus Infection and BronchiolitisPediatr Rev201435125193010.1542/pir.35-12-519

5 

U Kishore TJ Greenhough P Waters AK Shrive R Ghai MF Kamran Surfactant proteins SP-A and SP-D: Structure, function and receptorsMol Immunol2006439129331510.1016/j.molimm.2005.08.004

6 

GL Sorensen Surfactant Protein D in Respiratory and Non-Respiratory DiseasesFront Med201851810.3389/fmed.2018.00018

7 

A. M. Pastva J. R. Wright K. L. Williams Immunomodulatory Roles of Surfactant Proteins A and D: Implications in Lung DiseaseProce Am Thoracic Soc200743252710.1513/pats.200701-018aw

8 

MH Kerr JY Paton Surfactant Protein Levels in Severe Respiratory Syncytial Virus InfectionAm J Respir Crit Care Med199915941115810.1164/ajrccm.159.4.9709065

9 

H Clark K Reid The potential of recombinant surfactant protein D therapy to reduce inflammation in neonatal chronic lung disease, cystic fibrosis, and emphysemaArch Dis Child2003889815

10 

ER Barreira AR Precioso A Bousso Pulmonary surfactant in respiratory syncytial virus bronchiolitis: The role in pathogenesis and clinical implicationsPediatric Pulmonol20114654152010.1002/ppul.21395

11 

AM LeVine J Gwozdz J Stark M Bruno J Whitsett T Korfhagen Surfactant protein-A enhances respiratory syncytial virus clearance in vivoJ Clin Investig1999103710152110.1172/jci5849

12 

AM LeVine J Elliott JA Whitsett A Srikiatkhachorn E Crouch N DeSilva Surfactant Protein-D Enhances Phagocytosis and Pulmonary Clearance of Respiratory Syncytial VirusAm J Respir Cell Mol Biol2004312193910.1165/rcmb.2003-0107oc

13 

Y Kawasaki K Endo K Suyama M Sato M Ito K Hashimoto Serum SP-D levels as a biomarker of lung injury in respiratory syncytial virus bronchiolitisPediatr Pulmonol2011461182210.1002/ppul.21270

14 

L L Liu M M Gallaher R L Davis C M Rutter T C Lewis E K Marcuse Use of a respiratory clinical score among different providersPediatr Pulmonol2004373243810.1002/ppul.10425

15 

A Tal C Bavilski D Yohai J E Bearman R Gorodischer S W Moses Dexamethasone and salbutamol in the treatment of acute wheezing in infantsPediatr198371138

16 

CA Benne B Benaissa-Trouw JAG Van Strijp CA Kraaijeveld JF Iwaarden Surfactant protein A, but not surfactant protein D, is an opsonin for influenza A virus phagocytosis by rat alveolar macrophagesEur J Immunol19972748869010.1002/eji.1830270413

17 

JR Wright Immunomodulatory functions of surfactantPhysiol Rev19977749316210.1152/physrev.1997.77.4.931

18 

P A Dargaville M South P N McDougall Surfactant abnormalities in infants with severe viral bronchiolitis.Arch Dis Childhood1996752133610.1136/adc.75.2.133

19 

M A Chu E J Lee H J Park K H Lee W T Kim H L Chung Increased serum surfactant protein-D in the infants with acute respiratory syncytial virus bronchiolitisAllergy Asthma Respir Dis20131323540



jats-html.xsl


This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

  • Article highlights
  • Article tables
  • Article images

Article History

Received : 15-12-2020

Accepted : 02-01-2021


View Article

PDF File   Full Text Article


Copyright permission

Get article permission for commercial use

Downlaod

PDF File   XML File   ePub File


Digital Object Identifier (DOI)

Article DOI

https://doi.org/ 10.18231/j.ijpns.2020.023


Article Metrics






Article Access statistics

Viewed: 1459

PDF Downloaded: 650